{
    "clinical_study": {
        "@rank": "100820", 
        "acronym": "EVARREST\u2122 PMS", 
        "arm_group": [
            {
                "arm_group_label": "EVARREST\u2122 Fibrin Sealant Patch", 
                "arm_group_type": "Active Comparator", 
                "description": "EVARREST\u2122 Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component."
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Other", 
                "description": "Standard of Care (SoC) is manual compression with or without a topical absorbable hemostat."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the clinical utility of EVARREST\u2122 Fibrin Sealant\n      Patch (Fibrin Pad) as an adjunct to hemostasis in soft tissue bleeding during\n      intra-abdominal (stomach area), retroperitoneal (hip and stomach area), pelvic (hip area)\n      and non-cardiac thoracic (chest area) surgery."
        }, 
        "brief_title": "EVARREST\u2122 Fibrin Sealant Patch Post-Market Study", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hemorrhage", 
            "Soft Tissue Bleeding"
        ], 
        "condition_browse": {
            "mesh_term": "Hemorrhage"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects \u226518 years of age, requiring an elective or urgent, open intra-abdominal,\n             retroperitoneal, pelvic or non-cardiac thoracic surgical procedures;\n\n          -  Subjects must be willing to participate in the study and provide written informed\n             consent.\n\n          -  Presence of an appropriate Target Bleeding Site as identified intra-operatively by\n             the surgeon;\n\n        Exclusion Criteria:\n\n          -  Subjects with known intolerance to blood products or to one of the components of\n             EVARREST\u2122 or unwilling to receive blood products;\n\n          -  Female subjects who are pregnant or nursing.\n\n          -  TBS is from a large defect in an artery or vein where the injured vascular wall\n             requires repair and maintenance of vessel patency or where there would be persistent\n             exposure of EVARREST\u2122 to blood flow and/or pressure during  absorption of the\n             product;\n\n          -  TBS with major arterial bleeding requiring suture or mechanical ligation;\n\n          -  TBS within a contaminated or infected area of the body;\n\n          -  Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony\n             confine;\n\n          -  Subjects with any intra-operative findings identified by the surgeon that may\n             preclude conduct of the study procedure;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902459", 
            "org_study_id": "400-12-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "EVARREST\u2122 Fibrin Sealant Patch", 
                "intervention_name": "EVARREST\u2122 Fibrin Sealant Patch", 
                "intervention_type": "Biological", 
                "other_name": "EVARREST\u2122 Fibrin Sealant Patch"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fibrin Tissue Adhesive"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Hemostasis", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Clinical Site #1"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Non-Investigational Post-Market Trial Using EVARREST\u2122 Fibrin Sealant Patch as an Adjunct to Hemostasis in Soft Tissue Bleeding During Intra-Abdominal, Retroperitoneal, Pelvic and Non-Cardiac Thoracic Surgery", 
        "other_outcome": {
            "description": "Hemostasis Device Physician Ease of Use Questionnaire", 
            "measure": "Additional parameter", 
            "safety_issue": "No", 
            "time_frame": "Within 24-hours after surgery"
        }, 
        "overall_contact": {
            "email": "jbatill2@its.jnj.com", 
            "last_name": "Jonathan Batiller, MBA", 
            "phone": "908-218-2492"
        }, 
        "overall_official": {
            "affiliation": "Ethicon, Inc.", 
            "last_name": "Jerome Riebman, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of thromboembolic events\nIncidence of post-operative bleeding events specifically related to the target bleeding site (TBS)\nIncidence of increase blood fibrinogen levels", 
            "measure": "Safety Parameters Evaluated", 
            "safety_issue": "Yes", 
            "time_frame": "Up to the 30-day follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902459"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ethicon, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ethicon, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}